Operating Profit Margin
since 2018
Paying user area
Try for free
Moderna Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Total Asset Turnover since 2018
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Moderna Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Moderna Inc., operating profit margin, long-term trends, calculation
| Operating profit margin | = | 100 | × | Income (loss) from operations1 | ÷ | Product sales1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | = | 100 | × | ÷ | |||
| Dec 31, 2022 | = | 100 | × | ÷ | |||
| Dec 31, 2021 | = | 100 | × | ÷ | |||
| Dec 31, 2020 | = | 100 | × | ÷ | |||
| Dec 31, 2019 | = | 100 | × | ÷ | |||
| Dec 31, 2018 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$ in millions
- Income (loss) from operations
- The operating income shows significant volatility over the analyzed periods. Initially, there is an operating loss documented in 2018, 2019, and 2020, with losses deepening from -$413 million in 2018 to -$763 million in 2020. A notable shift occurs in 2021 with a substantial operating profit of $13,296 million, followed by a decrease to $9,420 million in 2022. In 2023, the company experienced a return to operating loss, amounting to -$4,239 million.
- Product sales
- Product sales were absent or negligible from 2018 to 2019, with the first recorded sales appearing in 2020 at $200 million. Thereafter, sales surged sharply to $17,675 million in 2021 and increased slightly to $18,435 million in 2022, before declining notably to $6,671 million in 2023. This pattern indicates a rapid growth phase followed by a considerable reduction in sales in the most recent year.
- Operating profit margin
- The operating profit margin reflects the fluctuations seen in income from operations. It was severely negative at -381.82% in 2020, indicating significant losses relative to sales. The margin improved remarkably to 75.22% in 2021, followed by a decrease to 51.1% in 2022, which still reflects high profitability. However, in 2023, the margin dropped back into negative territory at -63.54%, consistent with the operating loss reported.
Comparison to Competitors
Moderna Inc., operating profit margin, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | ||||||||
| Dec 31, 2022 | ||||||||
| Dec 31, 2021 | ||||||||
| Dec 31, 2020 | ||||||||
| Dec 31, 2019 | ||||||||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).